The Inflation Reduction Act: Unintended Consequences

9:45 AM - 10:30 AM (EDT), Monday, October 23, 2023 ・ Independence Ballroom
Rare disease patients are facing more challenging access issues than ever before, and implications of the Inflation Reduction Act (IRA) may complicate the future of rare disease research and development. Although CMS' final guidance on the drug price negotiation program included mechanisms for patient engagement, and cost smoothing, their interpretation of the IRA's orphan drug exemption may bring about unintended consequences.

Join us for a discussion with patient advocates about current policy priorities for rare disease patients and how the IRA may impact future rare disease pipelines.
Head, Strategic Alliance Development
Alexion Pharmaceuticals, Inc
Senior Director, Policy, Advocacy, & Patient Engagement
EveryLife Foundation for Rare Diseases
Senior Director, Policy and Regulatory Affairs
National Organization for Rare Disorders (NORD)
IRA Orphan Task Force